Results 291 to 300 of about 1,404,058 (313)

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

The Lancet Oncology, 2012
R. Rosell, E. Carcereny, R. Gervais, A. Vergnenègre, B. Massutí, E. Felip, R. Palmero, R. García-Gómez, C. Pallarés, J. Sánchez, R. Porta, M. Cobo, P. Garrido, F. Longo, T. Morán, A. Insa, F. de Marinis, R. Corre, I. Bover, A. Illiano, É. Dansin, J. de Castro, M. Milella, N. Reguart, G. Altavilla, U. Jiménez, M. Provencio, M. Moreno, J. Terrasa, J. Muñoz-Langa, J. Valdivia, D. Isla, M. Dómine, O. Molinier, J. Mazières, N. Baize, R. García-Campelo, G. Robinet, D. Rodríguez-Abreu, G. López-Vivanco, V. Gebbia, Lioba Ferrera-Delgado, P. Bombaron, R. Bernabé, A. Bearz, Á. Artal, E. Cortesi, C. Rolfo, M. Sánchez-Ronco, A. Drozdowskyj, C. Queralt, I. de Aguirre, J. Ramírez, J. Sánchez, M. Molina, M. Taron, L. Paz-Ares   +56 more
semanticscholar   +1 more source

Cancer Statistics, 2021

Ca-A Cancer Journal for Clinicians, 2021
Rebecca L Siegel, Kimberly D Miller
exaly  

Cancer statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal Dvm   +2 more
exaly  

Cancer statistics, 2023

Ca-A Cancer Journal for Clinicians, 2023
Rebecca L Siegel, Kimberly D Miller, Nikita Sandeep Wagle   +2 more
exaly  

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

The Lancet Oncology, 2010
T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, J. Tsurutani, T. Seto, M. Satouchi, H. Tada, T. Hirashima, K. Asami, N. Katakami, M. Takada, H. Yoshioka, K. Shibata, S. Kudoh, E. Shimizu, H. Saito, S. Toyooka, K. Nakagawa, M. Fukuoka   +20 more
semanticscholar   +1 more source

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Ca-A Cancer Journal for Clinicians, 2018
Frank Bray, Jacques Ferlay, Isabelle Soerjomataram   +2 more
exaly  

Cancer statistics, 2020

Ca-A Cancer Journal for Clinicians, 2020
Rebecca L Siegel, Kimberly D Miller
exaly  

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Journal of Clinical Oncology, 2003
M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, R. Eek, T. Horai, K. Noda, I. Takata, E. Smit, S. Averbuch, A. Macleod, A. Feyereislova, R. Dong, J. Baselga   +19 more
semanticscholar   +1 more source

Alectinib versus Crizotinib in Untreated ALK-Positive Nonâ?"Small-Cell Lung Cancer

2017
openaire   +1 more source

Cancer statistics, 2019

Ca-A Cancer Journal for Clinicians, 2019
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal Dvm   +2 more
exaly